Sara Tabatabai
Overview
Explore the profile of Sara Tabatabai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
1
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang P, OConnell K, Bhimani J, Blinder V, Burganowski R, Ergas I, et al.
JCO Clin Cancer Inform
. 2025 Feb;
9:e2400231.
PMID: 39951671
Purpose: We evaluated the definitions of five comorbidities (renal and hepatic impairments, anemia, neutropenia, and thrombocytopenia) in women with breast cancer using data from electronic health records. Methods: In 11,097...
2.
Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy
Saririan N, Bhamidipati D, Dey P, Persaud S, Chakraborty N, Tabatabai S, et al.
JNCI Cancer Spectr
. 2024 Nov;
8(6).
PMID: 39589914
Background: The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur. Methods: We studied NCCN Guidelines panelists for the...
3.
Mitchell A, Persaud S, Mishra Meza A, Fuchs H, De P, Tabatabai S, et al.
J Clin Oncol
. 2024 Oct;
43(5):524-535.
PMID: 39393041
Purpose: The Medicare part D Low-Income Subsidy (LIS) improves access to oral cancer drugs, but provides no assistance for clinician-administered/part B drugs. This analysis assessed the association between LIS participation...
4.
Bhimani J, OConnell K, Persaud S, Blinder V, Burganowski R, Ergas I, et al.
Breast Cancer Res Treat
. 2024 Aug;
208(2):405-414.
PMID: 39150586
Purpose: The National Comprehensive Cancer Network (NCCN) guidelines recommend a variety of drug combinations with specific administration schedules for the treatment of early-stage breast cancer, allowing physicians to deliver treatments...
5.
Bhimani J, OConnell K, Persaud S, Blinder V, Burganowski-Doud R, Ergas I, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Jul;
33(10):1286-1297.
PMID: 39051907
Background: Guidelines informing chemotherapy regimen selection are based on clinical trials with participants who do not necessarily represent general populations with breast cancer. Understanding who receives nonguideline regimens is important...
6.
Bhimani J, OConnell K, Persaud S, Blinder V, Burganowski R, Ergas I, et al.
Int J Cancer
. 2024 Jul;
155(9):1577-1592.
PMID: 38970396
For patients with breast cancer, delays in chemotherapy initiation have been adversely associated with recurrence and survival. We evaluated patient-level factors associated with delayed chemotherapy initiation, from both diagnosis and...
7.
Bhimani J, OConnell K, Ergas I, Foley M, Gallagher G, Griggs J, et al.
Breast Cancer Res
. 2024 Jun;
26(1):101.
PMID: 38872192
Background: Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal...
8.
Bhimani J, OConnell K, Ergas I, Foley M, Gallagher G, Griggs J, et al.
JCO Clin Cancer Inform
. 2024 Apr;
8:e2300209.
PMID: 38635936
Purpose: Identification of patients' intended chemotherapy regimens is critical to most research questions conducted in the real-world setting of cancer care. Yet, these data are not routinely available in electronic...